103733-66-0 Usage
Description
(S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride is an organic compound with a unique chemical structure, characterized by its isoquinoline core and methoxy substituents. It is a key intermediate in the synthesis of various pharmaceutical compounds and has potential applications in the development of new drugs.
Uses
Used in Pharmaceutical Industry:
(S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride is used as a reactant for the preparation of core scaffolds, including 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. This core scaffold is essential in the development of direct coagulation factor Xa (FXa) inhibitors, which are crucial in the treatment of various thrombotic disorders and have potential applications in the prevention and treatment of blood clot-related conditions.
Additionally, due to its unique chemical structure, (S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride may also be used as a building block for the synthesis of other bioactive compounds with potential applications in various therapeutic areas, such as central nervous system disorders, cardiovascular diseases, and oncology.
Check Digit Verification of cas no
The CAS Registry Mumber 103733-66-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,7,3 and 3 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 103733-66:
(8*1)+(7*0)+(6*3)+(5*7)+(4*3)+(3*3)+(2*6)+(1*6)=100
100 % 10 = 0
So 103733-66-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H15NO4.ClH/c1-16-10-4-7-3-9(12(14)15)13-6-8(7)5-11(10)17-2;/h4-5,9,13H,3,6H2,1-2H3,(H,14,15);1H
103733-66-0Relevant articles and documents
Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives
Breen, Christopher P.,Jamison, Timothy F.
supporting information, p. 14527 - 14531 (2019/11/03)
A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types
Klutchko,Blankley,Fleming,Hinkley,Werner,Nordin,Holmes,Hoefle,Cohen,Essenburg
, p. 1953 - 1961 (2007/10/02)
-
